These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 17889154)

  • 1. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation.
    Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy.
    Sato T; Inagaki A; Uchida K; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Tominaga Y; Okajima Y; Ohta K; Suga H; Taguchi S; Kakiya S; Itatsu T; Kobayashi T; Nakao A
    Transplantation; 2003 Nov; 76(9):1320-6. PubMed ID: 14627910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus.
    Oberholzer J; Thielke J; Hatipoglu B; Testa G; Sankary HN; Benedetti E
    Transplant Proc; 2005 Mar; 37(2):999-1000. PubMed ID: 15848603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature.
    Ghisdal L; Bouchta NB; Broeders N; Crenier L; Hoang AD; Abramowicz D; Wissing KM
    Transpl Int; 2008 Feb; 21(2):146-51. PubMed ID: 17971033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO
    Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
    Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
    Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.
    Gnatta D; Keitel E; Heineck I; Cardoso BD; Rodrigues AP; Michel K; Garcia VD
    Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R; Chahin J; Alarcón A; Bravo J
    Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
    Waid T;
    Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients.
    Chang HR; Lin CC; Lian JD
    Transplant Proc; 2007 Dec; 39(10):3135-41. PubMed ID: 18089339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients.
    Kanbay M; Akcay A; Huddam B; Usluogullari CA; Arat Z; Ozdemir FN; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3119-20. PubMed ID: 16213325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplant diabetes mellitus: incidence and risk factors.
    Mazali FC; Lalli CA; Alves-Filho G; Mazzali M
    Transplant Proc; 2008 Apr; 40(3):764-6. PubMed ID: 18455010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients.
    Numakura K; Satoh S; Tsuchiya N; Horikawa Y; Inoue T; Kakinuma H; Togashi H; Matsuura S; Tada H; Suzuki T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1865-7. PubMed ID: 15919487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to tacrolimus extended-release formulation: short-term clinical results.
    Gallego-Valcarce E; Ortega-Cerrato A; Llamas-Fuentes F; Martinez-Fernandez G; Perez-Martinez J; Gomez-Roldan C
    Transplant Proc; 2009; 41(6):2326-7. PubMed ID: 19715909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.